PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

NAActive, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

Dose escalation

This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT03663218 - PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) | Biotech Hunter | Biotech Hunter